---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091199"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:49:56.442654+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Orthofix Q2 net sales $198.6M (+6% YoY); raises FY2024 guidance

## Summary
- Q2 net sales $198.6M, +6% YoY; net loss $(33.4M) vs $(39.4M) prior year; EPS $(0.88).
- Non-GAAP adjusted EBITDA $16.6M (8.4% margin), +310 bps YoY from $9.9M.
- Bone Growth Therapies +12% YoY; U.S. Spine Fixation +12% YoY; Global Orthopedics +5%.
- FY2024 net sales guidance raised to $795-800M; adjusted EBITDA to $64-69M.
- Expects positive free cash flow in H2 2024; appointed four new executive team members.

## SEC filing metadata
- accession: 0000950170-24-091199
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000095017024091199/0000950170-24-091199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000095017024091199/ofix-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091199
- JSON: https://secwatch.observer/filing/0000950170-24-091199.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.